Products

Vernix

Skill

AI agent that joins calls with live data from your tools

vernix.app Productivity & Collaboration / Meetings & Note-Takers

AI Benchmark
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
No monthly subscription pricing
Creators
Pauli Mankinen
No social account linked
Launched
7mo ago
2026-04-07 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    AI agent that joins calls with live data from your tools

    Apr 7 · 7mo agoLaunch page

MCP Server & Agent Ecosystem

GitHub · MCP / Skill

Agent, MCP & Developer Integration

Agent Skill
Exposed tool capabilities:
Meeting Notes
Browse developer & CLI tools →

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Direct36%
  • Organic Search33%
  • Referrals11%
  • Social6%
  • Other13%

Countries

  • Croatia100%

Search

Domain authority —Domain registered 2026-03-24

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2026-04-07

Key pages

Weekly snapshots

No page snapshots yet. Once followed, home and pricing pages are captured weekly.

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does Vernix get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Vernix and what platforms does it support?
Vernix is catalogued under Meetings & Note-Takers: AI agent that joins calls with live data from your tools. Supported platforms: Web.

Related products in this category

Productivity & Collaboration / Meetings & Note-Takers

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.